Genome editing in vascular endothelial cells made possible with a powerful new delivery system

Children's Health

Products You May Like

Northwestern Medicine scientists developed a unique nanoparticle to deliver genome editing technology, including CRISPR/Cas9, to endothelial cells, which line blood vessel walls.

Published in Cell Reports, this is the first time that vascular endothelial cells could be reached for genome editing, since the usual way to deliver CRISPR/Cas9 – through a virus – does not work for this cell type, according to YouYang Zhao, PhD, professor of Pediatrics in the Division of Critical Care and senior author of the study.

The nanoparticle we developed is a powerful new delivery system for genome editing in vascular endothelial cells, and could be used to treat many diseases, including acute respiratory distress syndrome from severe COVID-19. With this nanoparticle we can introduce genes to inhibit vascular injury or promote vascular repair, correct gene mutations and turn genes on or off to restore normal function. It also allows us to edit multiple genes at the same time. This is an important advance for treating any disease caused by endothelial dysfunction.”

YouYang Zhao, PhD, member of the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago

Endothelial dysfunction is at the root of many diseases, such as coronary artery disease, stroke, bronchopulmonary dysplasia and pulmonary artery hypertension. Zhao explained that genome editing in endothelial cells could even treat cancers by cutting off the blood supply to the tumor or blocking cancer metastasis.

At this stage, Dr. Zhao and colleagues achieved excellent results in a mouse model. The nanoparticle carrying CRISPR/Cas9 plasmid DNA was introduced via a one-time IV injection and required a few days to be effective. Preclinical testing will be necessary before clinical trials can begin.

“Our nanoparticle delivery system for genome editing and transgene expression also is a huge advance for cardiovascular research,” Zhao added.

Journal reference:

Zhang, X., et al. (2022) Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA. Cell Reports. doi.org/10.1016/j.celrep.2021.110196.

Products You May Like

Articles You May Like

Labial fusion isn’t the bizarre medical anomaly you might think
Can probiotics prevent ear infections and tonsilitis?
5 Ways to Have a Healthy Coparenting Relationship after Divorce
The CRA may owe you money from years ago—and there’s an easy way to check
Newborn sleep: 7 common mistakes new parents make
This TikTok mom found the simplest way to keep toddlers entertained
I wish I hadn’t waited so long to get meds for my PPD
Study finds a steep rise in type 2 diabetes among children during the COVID-19 pandemic
Youth-onset type 2 diabetes climbed 77% amid COVID-19, study shows
It’s Black Breastfeeding Week—here’s why that matters
Penn-CHOP Kidney Innovation Center focuses on early detection, prevention, and treatment of kidney disease
13 best nursing bras that are actually comfortable

Leave a Reply

Your email address will not be published.